First Patient Dosed in Phase 3 oPTimize Trial of Canvuparatide
MBX Biosciences has begun dosing the first patient in its Phase 3 oPTimize trial of canvuparatide for chronic hypoparathyroidism, positioning it as potential best‑in‑class PTH replacement therapy.
Key Takeaways
- MBX Biosciences dosed the first patient in the Phase 3 oPTimize trial of once‑weekly canvuparatide.
- The trial follows positive Phase 2 Avail™ results and one‑year open‑label extension data showing sustained physiologic PTH replacement effects.
- The global registrational study plans to enroll ~160 adults, with a 26‑week double‑blind period followed by a 78‑week open‑label extension.
What is the Phase 3 oPTimize trial targeting?
MBX Biosciences dosed the first patient in Phase 3 oPTimize, a global, randomized, double‑blind, placebo‑controlled trial testing once‑weekly canvuparatide in adults with chronic hypoparathyroidism MBX Biosciences press release. The trial builds on sustained physiologic effects observed in Phase 2 Avail™ and a year‑long open‑label extension: normalization of serum calcium, reduced urinary calcium excretion, restored bone metabolism, and improved eGFR MBX Biosciences press release.
How is trial design informed by earlier data?
MBX structured oPTimize using lessons from Avail™. The design includes a 26‑week double‑blind period starting with fixed dosing at 600 µg weekly, followed by an 18‑week titration up to 1,600 µg and a 4‑week maintenance phase without changes to study drug, active vitamin D, or calcium supplements MBX Biosciences press release. This mirrors the dosing flexibility needed to sustain physiologic PTH activity shown in Phase 2 results and the one‑year extension, where normal calcium homeostasis and stable exposure supported once‑weekly administration MBX Biosciences press release.
How large and long is the oPTimize trial?
The study plans to enroll approximately 160 adults with chronic hypoparathyroidism, randomized 3:1 to canvuparatide or placebo during the double‑blind period, followed by a 78‑week open‑label extension MBX Biosciences press release. The primary endpoint at Week 26 measures a composite response: normal albumin‑adjusted serum calcium, independence from active vitamin D, calcium supplementation ≤600 mg/day, and no recent dose increases MBX Biosciences press release.
FAQ
What is Phase 3 oPTimize?
Phase 3 oPTimize is MBX Biosciences’ global, pivotal trial evaluating once‑weekly canvuparatide as a PTH replacement for chronic hypoparathyroidism.
Who is sponsoring the Phase 3 oPTimize study?
MBX Biosciences sponsors and conducts the Phase 3 oPTimize trial for canvuparatide in chronic hypoparathyroidism.
What makes canvuparatide a potential best‑in‑class PTH replacement therapy?
Canvuparatide showed sustained physiologic effects in Phase 2 and one‑year open‑label data, including calcium normalization, reduced urinary calcium, improved bone metabolism, and eGFR, supporting its once‑weekly design and potential best‑in‑class profile.
How many patients will enroll in Phase 3 oPTimize?
The trial aims to enroll approximately 160 adult patients with chronic hypoparathyroidism.
What is the primary endpoint of Phase 3 oPTimize?
The primary endpoint at Week 26 measures a composite response: normal albumin‑adjusted serum calcium, independence from active vitamin D, calcium supplementation ≤600 mg/day, and no dose increases in the preceding four weeks.
Note: This article is for general information and is not medical advice. Talk to a licensed clinician before using any peptide product.